Patent Foramen Ovale and Cryptogenic Stroke: Integrated Management

F. Luca*, P.G. Pino, I. Parrini, S.A. Di Fusco, R. Ceravolo, A. Madeo, A. Leone, M. La Mair, F.A. Benedetto, C. Riccio, F. Oliva, F. Colivicchi, M.M. Gulizia, S. Gelsomino*

*Corresponding author for this work

Research output: Contribution to journal(Systematic) Review article peer-review

Abstract

Patent foramen ovale (PFO) is a common cardiac abnormality with a prevalence of 25% in the general population. PFO has been associated with the paradoxical embolism causing cryptogenic stroke and systemic embolization. Results from clinical trials, meta-analyses, and position papers support percutaneous PFO device closure (PPFOC), especially if interatrial septal aneurysms coexist and in the presence of large shunts in young patients. Remarkably, accurately evaluating patients to refer to the closure strategy is extremely important. However, the selection of patients for PFO closure is still not so clear. The aim of this review is to update and clarify which patients should be considered for closure treatment.
Original languageEnglish
Article number1952
Number of pages15
JournalJournal of Clinical Medicine
Volume12
Issue number5
DOIs
Publication statusPublished - 1 Mar 2023

Keywords

  • Patent foramen ovale (PFO)
  • device closure
  • interatrial septal aneurysms
  • PFO-associated syndromes
  • cryptogenic stroke
  • TO-LEFT SHUNT
  • ATRIAL-FIBRILLATION DETECTION
  • ACUTE ISCHEMIC-STROKE
  • PERCUTANEOUS CLOSURE
  • TRANSCATHETER CLOSURE
  • TRANSCRANIAL DOPPLER
  • MEDICAL THERAPY
  • PFO CLOSURE
  • TRANSTHORACIC ECHOCARDIOGRAPHY
  • SECONDARY PREVENTION

Cite this